Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
